JP2003524577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003524577A5 JP2003524577A5 JP2000518662A JP2000518662A JP2003524577A5 JP 2003524577 A5 JP2003524577 A5 JP 2003524577A5 JP 2000518662 A JP2000518662 A JP 2000518662A JP 2000518662 A JP2000518662 A JP 2000518662A JP 2003524577 A5 JP2003524577 A5 JP 2003524577A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- treatment
- need
- tables
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 201000004384 Alopecia Diseases 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 201000007094 prostatitis Diseases 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Description
【特許請求の範囲】
【請求項１】 5α-還元酵素を表1〜7のいずれかに示す有効阻害量の化合物に暴露するステップを含む5α-還元酵素活性を阻害する方法。
【請求項２】 表1〜7のいずれかに示す有効治療量を前立腺癌の治療を必要とする被験者に投与するステップを含む前立腺癌の治療を必要とする被験者の前立腺癌を治療する方法。
【請求項３】 表1〜7のいずれかに示す有効治療量を乳癌の治療を必要とする被験者に投与するステップを含む乳癌の治療を必要とする被験者の乳癌を治療する方法。
【請求項４】 表1〜7のいずれかに示す有効治療量を脱毛症の治療を必要とする被験者に投与するステップを含む脱毛症の治療を必要とする被験者の脱毛症を治療する方法。
【請求項５】 表1〜7のいずれかに示す有効治療量を皮膚疾患の治療を必要とする被験者に投与するステップを含む皮膚疾患の治療を必要とする被験者の皮膚疾患を治療する方法。
【請求項６】 表1〜7のいずれかに示す有効治療量を肥満の治療を必要する被験者に投与するステップを含む肥満の治療を必要する被験者の肥満を治療する方法。
【請求項７】 表1〜7のいずれかに示す有効治療量を良性前立腺肥大又は前立腺炎の治療を必要とする被験者に投与するステップを含む良性前立腺肥大又は前立腺炎の治療を必要とする被験者の良性前立腺肥大又は前立腺炎を治療する方法。
【請求項８】 式
【化１】
（式中、xは-NHCH2CH2-又はCH=CH-であり、R1、R2及びR3は各々-H、-OH又はOCH3であってもよいが、ただしR1、R2及びR3のうち1つだけは-Hであってよく、R4、R5及びR6は各々-H、-OH、-OCH3又はN（CH3）2であってもよいが、ただしR4、R5及びR6のうち1つだけは-Hであってもよく、nは0又は1である。）
の化合物。
【請求項９】 式
【化２】
（式中、Rは、炭素、酸素、硫黄及び窒素からなる一群から選ばれる2〜20の原子を有する鎖であり、1〜4の二重結合と追加の水素を有しても、有さなくてもよい鎖である。）
の化合物。
【請求項１０】 式
【化３】
（式中、Rは、
【化４】
【化５】
である。）
の化合物。
【請求項１１】 表１〜７に示す化合物の治療用製剤の酸性度をpH 3.0〜 6.8に維持するために無機酸、有機酸又はこれらの酸を含む天然物の有効量を添加するステップを含む、表1〜7に示す化合物を安定化するための方法。
【請求項１】 5α-還元酵素を表1〜7のいずれかに示す有効阻害量の化合物に暴露するステップを含む5α-還元酵素活性を阻害する方法。
【請求項２】 表1〜7のいずれかに示す有効治療量を前立腺癌の治療を必要とする被験者に投与するステップを含む前立腺癌の治療を必要とする被験者の前立腺癌を治療する方法。
【請求項３】 表1〜7のいずれかに示す有効治療量を乳癌の治療を必要とする被験者に投与するステップを含む乳癌の治療を必要とする被験者の乳癌を治療する方法。
【請求項４】 表1〜7のいずれかに示す有効治療量を脱毛症の治療を必要とする被験者に投与するステップを含む脱毛症の治療を必要とする被験者の脱毛症を治療する方法。
【請求項５】 表1〜7のいずれかに示す有効治療量を皮膚疾患の治療を必要とする被験者に投与するステップを含む皮膚疾患の治療を必要とする被験者の皮膚疾患を治療する方法。
【請求項６】 表1〜7のいずれかに示す有効治療量を肥満の治療を必要する被験者に投与するステップを含む肥満の治療を必要する被験者の肥満を治療する方法。
【請求項７】 表1〜7のいずれかに示す有効治療量を良性前立腺肥大又は前立腺炎の治療を必要とする被験者に投与するステップを含む良性前立腺肥大又は前立腺炎の治療を必要とする被験者の良性前立腺肥大又は前立腺炎を治療する方法。
【請求項８】 式
【化１】
の化合物。
【請求項９】 式
【化２】
の化合物。
【請求項１０】 式
【化３】
【化４】
の化合物。
【請求項１１】 表１〜７に示す化合物の治療用製剤の酸性度をpH 3.0〜 6.8に維持するために無機酸、有機酸又はこれらの酸を含む天然物の有効量を添加するステップを含む、表1〜7に示す化合物を安定化するための方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6377097P | 1997-10-31 | 1997-10-31 | |
| US60/063,770 | 1997-10-31 | ||
| PCT/US1998/023041 WO1999022728A1 (en) | 1997-10-31 | 1998-10-30 | Methods and compositions for regulation of 5-alpha reductase activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003524577A JP2003524577A (ja) | 2003-08-19 |
| JP2003524577A5 true JP2003524577A5 (ja) | 2006-02-23 |
| JP4738592B2 JP4738592B2 (ja) | 2011-08-03 |
Family
ID=22051389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000518662A Expired - Lifetime JP4738592B2 (ja) | 1997-10-31 | 1998-10-30 | ５α−還元酵素活性を調節するための方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6576660B1 (ja) |
| EP (1) | EP1027045A4 (ja) |
| JP (1) | JP4738592B2 (ja) |
| KR (1) | KR20010031501A (ja) |
| AU (1) | AU1289899A (ja) |
| WO (1) | WO1999022728A1 (ja) |
Families Citing this family (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385936A (en) | 1990-07-12 | 1995-01-31 | The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services | Gossypol acetic acid for the treatment of cancer |
| US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
| US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| JP4738592B2 (ja) | 1997-10-31 | 2011-08-03 | アーチ・デヴェロップメント・コーポレイション | ５α−還元酵素活性を調節するための方法及び組成物 |
| US5958946A (en) * | 1998-01-20 | 1999-09-28 | Styczynski; Peter | Modulation of hair growth |
| IL142650A (en) * | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| GB0000710D0 (en) * | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
| US7087592B1 (en) | 1999-08-23 | 2006-08-08 | Entre Med, Inc. | Compositions comprising purified 2-methoxyestradiol and methods of producing same |
| GB9920548D0 (en) * | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| KR20050047546A (ko) * | 1999-10-29 | 2005-05-20 | 다카라 바이오 가부시키가이샤 | 의약, 음료 또는 식품 |
| FI20000004A0 (fi) * | 2000-01-03 | 2000-01-03 | Slk Foundation | Flavonoidilääke... |
| FR2803749B1 (fr) * | 2000-01-18 | 2006-09-22 | Pharmascience Lab | Utilisation d'au moins un ester gras pour la preparation d'une composition destinee a inhiber l'activite de la 5 alpha-reductase, en pharmacie notamment en dermatologie, en cosmetique et en tant qu'additif alimentaire |
| FR2803747B1 (fr) * | 2000-01-18 | 2003-12-26 | Pharmascience Lab | Utilisation d'isoflavones et/ou d'extraits de prunier d'afrique en pharmacie, cosmetique et en tant qu'additif alimentaire. |
| CN1392796A (zh) * | 2000-02-18 | 2003-01-22 | 亚其发展公司 | 含多羟基苯化合物 |
| US6610749B2 (en) | 2000-02-18 | 2003-08-26 | Arch Development Corporation | Polyhydroxylated benzene-containing compounds |
| US6518261B2 (en) * | 2000-03-17 | 2003-02-11 | Oncology Sciences Corporation | Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers |
| WO2001074345A2 (en) * | 2000-03-31 | 2001-10-11 | Jonathan Ingram | Isoflavones for treatment of obesity |
| FR2808192A1 (fr) * | 2000-04-28 | 2001-11-02 | Oreal | Epichatechine comme inhibiteur de no-synthase et utilisations |
| US7084126B1 (en) * | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| DE10029770A1 (de) * | 2000-06-16 | 2001-12-20 | Transmit Technologietransfer | Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren |
| CA2417500C (en) * | 2000-07-28 | 2008-11-18 | Georgetown University Medical Center | Erbb-2 selective small molecule kinase inhibitors |
| US7135581B2 (en) | 2000-08-18 | 2006-11-14 | Entremed, Inc. | Antiangiogenic agents |
| FR2817749A1 (fr) * | 2000-12-13 | 2002-06-14 | Aventis Pharma Sa | Nouvelle utilisation des composes de la classe des chalcones |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6555573B2 (en) | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
| AR033855A1 (es) | 2001-01-26 | 2004-01-07 | Schering Corp | Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxis0mal (ppar) e inhibidor(es) de absorcion de esterol, el uso de dichas composiciones o combinaciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares, diabetes, obes |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| TWI337076B (en) | 2001-01-26 | 2011-02-11 | Schering Corp | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| WO2002062349A1 (en) * | 2001-02-05 | 2002-08-15 | Oncology Sciences Corporation | Method and composition for inhibiting the incidence and proliferation of nervous system and brain cancer cells |
| ITVR20010031A1 (it) * | 2001-03-12 | 2002-09-12 | Hisanori Suzuki | Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative. |
| WO2002076448A1 (en) * | 2001-03-23 | 2002-10-03 | Napro Biotherapeutics, Inc. | Molecular conjugates for use in treatment of cancer |
| PL205635B1 (pl) * | 2001-04-09 | 2010-05-31 | Inst Farmaceutyczny | Nowe pochodne genisteiny i zawierające je środki farmaceutyczne |
| US8975246B2 (en) | 2001-04-17 | 2015-03-10 | Galmed Research And Development Ltd. | Bile acid or bile salt fatty acid conjugates |
| US7432304B2 (en) * | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| PT1429756E (pt) | 2001-09-21 | 2007-01-31 | Schering Corp | Tratamento de xantoma com derivados de azetidinona como inibidores de absorção de esteróis |
| JP4179494B2 (ja) * | 2001-10-23 | 2008-11-12 | 株式会社カネカ | ペルオキシソーム増殖剤応答性受容体リガンド剤 |
| AU2002360335A1 (en) * | 2001-11-01 | 2003-05-12 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at bcl-2 |
| IL161625A0 (en) | 2001-11-19 | 2004-09-27 | Medigene Ag | Medicament for the treatment of viral skin and tumour diseases |
| US20030236439A1 (en) * | 2002-01-30 | 2003-12-25 | Gregory Agoston | Non-steroidal analogs of 2-methoxyestradiol |
| AU2003226974A1 (en) * | 2002-02-12 | 2003-09-04 | Hunza Di Pistolesi Elvira And C. S.A.S. | N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
| US7972632B2 (en) | 2003-02-28 | 2011-07-05 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
| US7108868B2 (en) | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
| EP1348421A3 (fr) * | 2002-03-25 | 2004-01-02 | L'oreal | Procédé de densification ou de coiffage des fibres kératiniques humaines utilisant un système catalytique particulier |
| FR2847805B1 (fr) * | 2002-11-28 | 2005-01-07 | Oreal | Procede de densification des fibres keratiniques humaines utilisant un systeme catalytique particulier |
| US20050171084A1 (en) * | 2002-03-27 | 2005-08-04 | Cairns William J. | Methods of treatment with lxr modulators |
| US7355081B2 (en) | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| US6790979B2 (en) * | 2002-04-17 | 2004-09-14 | University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| US8034387B2 (en) | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| CN101837003B (zh) | 2002-04-30 | 2013-09-04 | 尤尼根公司 | 作为治疗剂的包含无取代b环类黄酮和黄烷混合物的组合物 |
| US7790706B2 (en) | 2002-06-14 | 2010-09-07 | The University Of Edinburgh | Treatment of inflammation with 5α reduced metabolites |
| GB0213745D0 (en) * | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| AU2007229399B2 (en) * | 2002-06-21 | 2010-12-23 | L'oreal | Use of taurine or derivatives thereof for the treatment of alopecia |
| ES2774911T3 (es) | 2002-06-21 | 2020-07-23 | Oreal | Utilización de la taurina o derivados para el tratamiento de la alopecia |
| AU2003266313B2 (en) * | 2002-08-27 | 2009-10-22 | Societe Des Produits Nestle S.A. | Preventing or treating epithelial tissue damage or hair loss |
| US7083813B2 (en) * | 2002-11-06 | 2006-08-01 | The Quigley Corporation | Methods for the treatment of peripheral neural and vascular ailments |
| AU2003291719A1 (en) | 2002-11-06 | 2004-06-03 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| US20040097429A1 (en) * | 2002-11-18 | 2004-05-20 | Nieuwenhuizen Arie Gijsbert | Method for the reduction of the mammalian appetite |
| US7122573B2 (en) | 2002-12-06 | 2006-10-17 | Sri International | Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents |
| WO2004073707A1 (en) * | 2003-02-19 | 2004-09-02 | Unilever N.V. | Topical composition containing alkyl gallate or alkyl hydroxybenzoate or phenol alkyloxy as agent against acne |
| BRPI0407893A (pt) * | 2003-02-26 | 2006-03-01 | Unigen Pharmaceuticals Inc | formulação para uso na prevenção e tratamento de doenças e condições induzidas por carboidrato |
| CN1756755A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| CA2517572C (en) | 2003-03-07 | 2011-12-13 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| MXPA05009503A (es) | 2003-03-07 | 2005-10-18 | Schering Corp | Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| US7326734B2 (en) * | 2003-04-01 | 2008-02-05 | The Regents Of The University Of California | Treatment of bladder and urinary tract cancers |
| CA2521429A1 (en) | 2003-04-04 | 2004-10-21 | Unigen Pharmaceuticals, Inc. | Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care |
| WO2004112696A2 (en) * | 2003-05-20 | 2004-12-29 | Erimos Pharmaceutical Llp | Methods and compositions for delivery of catecholic butanes for treatment of diseases |
| JP2006526025A (ja) | 2003-05-28 | 2006-11-16 | エントレメッド インコーポレイテッド | 抗血管新生剤 |
| FR2856304B1 (fr) * | 2003-06-20 | 2006-03-03 | Natural Product Consulting | Composition pour la prevention des infections du systeme urinaire |
| US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| EP1648437A2 (en) * | 2003-07-01 | 2006-04-26 | President And Fellows Of Harvard College | Sirt1 modulators for manipulating cell/organism lifespan/stress response |
| FR2857266B1 (fr) * | 2003-07-07 | 2007-09-21 | Jean Noel Thorel | Composition a usage dermatologique et/ou cosmetique, comprenant a titre de principe actif au moins un antioxydant lipophile |
| US20050008712A1 (en) * | 2003-07-08 | 2005-01-13 | Debasis Bagchi | Compositions incorporating high-caffeine green tea extract and related methods for promoting healthy body weight |
| FR2859104A1 (fr) * | 2003-08-29 | 2005-03-04 | Saint Laurent Parfums | Molecules a activite anti-adipogenique sur cellules adipocytaires humaines |
| JP4917889B2 (ja) * | 2003-09-25 | 2012-04-18 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． | アミロイド関連疾患を処置するための組成物及びその使用方法 |
| NZ546323A (en) * | 2003-10-09 | 2009-04-30 | Medigene Ag | The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin |
| US20050079235A1 (en) * | 2003-10-09 | 2005-04-14 | Eggert Stockfleth | Use of a polyphenol for the treatment of actinic keratosis |
| KR20050037102A (ko) * | 2003-10-17 | 2005-04-21 | 한국 한의학 연구원 | 비만 억제용 조성물 |
| AU2004289229B8 (en) * | 2003-11-05 | 2010-10-07 | Osteoscreen, Inc. | Stimulation of hair growth by Ginkgo biloba flavanoids |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| CN101247793B (zh) * | 2003-12-29 | 2013-04-10 | 哈佛大学校长及研究员协会 | 治疗或预防肥胖和胰岛素抗性病症的组合物 |
| ES2809302T3 (es) | 2004-01-22 | 2021-03-03 | Univ Miami | Formulaciones de coenzima Q10 para tratar tumores sólidos mediante administración intravenosa |
| EP1566439A1 (en) * | 2004-02-20 | 2005-08-24 | Nestec S.A. | Preventing or treating obesity |
| CA2558014A1 (en) | 2004-03-12 | 2005-09-29 | Entremed, Inc. | Antiangiogenic agents |
| JP2007530568A (ja) * | 2004-03-25 | 2007-11-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ゴシポール共結晶およびその使用 |
| JP4904498B2 (ja) * | 2004-03-29 | 2012-03-28 | 財団法人ヒューマンサイエンス振興財団 | Ｒａｒ活性化を起こす天然化合物 |
| US20080125403A1 (en) * | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US20050267221A1 (en) * | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of curcumin and analogues thereof as inhibitors of ACC2 |
| JP3790767B2 (ja) * | 2004-06-30 | 2006-06-28 | 森下仁丹株式会社 | 脂肪代謝改善組成物 |
| WO2006004722A2 (en) * | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
| US20060009430A1 (en) * | 2004-07-01 | 2006-01-12 | Kelly Gregory J | Composition for the prevention and treatment of the detrimental effects of dihydrotestosterone |
| US9216161B2 (en) | 2004-08-13 | 2015-12-22 | Healthpartners Research Foundation | Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity |
| US7618615B2 (en) | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
| US7544816B2 (en) | 2004-08-19 | 2009-06-09 | The Hong Kong Polytechnic University | (−)-Epigallocatechin gallate derivatives for inhibiting proteasome |
| US8193377B2 (en) | 2004-08-19 | 2012-06-05 | The Hong Kong Polytechnic University | (−)-epigallocatechin gallate derivatives for inhibiting proteasome |
| EP1841415A2 (en) * | 2005-01-20 | 2007-10-10 | Sirtris Pharmaceuticals, Inc. | Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
| JPWO2006080328A1 (ja) * | 2005-01-26 | 2008-06-19 | サントリー株式会社 | カテキン類のエステル化物、その製造方法、および該エステル化物を含む飲食品あるいは化粧品 |
| US8435576B2 (en) * | 2005-01-28 | 2013-05-07 | Barry Callebaut Ag | Use of cocoa polyphenols for treating a prostate hyperplasia, a specific cocoa extract and applications |
| WO2006104762A2 (en) | 2005-03-25 | 2006-10-05 | Merck & Co., Inc. | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor |
| AU2006236633B2 (en) * | 2005-04-15 | 2012-03-29 | Albert Einstein College Of Medicine Of Yeshiva University | Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy |
| WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| KR101273027B1 (ko) * | 2005-08-20 | 2013-06-10 | (주)아모레퍼시픽 | 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물 |
| FR2892923B1 (fr) | 2005-11-08 | 2009-01-16 | Engelhard Lyon Sa | Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques. |
| FR2893026B1 (fr) * | 2005-11-08 | 2010-09-17 | Polaris | Nouveaux derives polyphenoliques liposolubles et leur utilisation comme antioxidants |
| US7700136B2 (en) * | 2005-11-14 | 2010-04-20 | Bionovo, Inc. | Scutellaria barbata extract for the treatment of cancer |
| US7537774B2 (en) * | 2005-12-23 | 2009-05-26 | Orion Therapeautics, Llc | Therapeutic formulation |
| JP2007197387A (ja) * | 2006-01-27 | 2007-08-09 | Maruzen Pharmaceut Co Ltd | テストステロン５α−レダクターゼ阻害剤 |
| WO2007109312A2 (en) | 2006-03-20 | 2007-09-27 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
| CA2656613A1 (en) * | 2006-07-03 | 2008-01-10 | Genmab A/S | Prevention of rash in patients undergoing anti-egfr therapy |
| WO2008065527A2 (en) * | 2006-11-27 | 2008-06-05 | Carlo Ghisalberti | Gallic acid esters of fragrant alcohols |
| EP1950210B1 (fr) * | 2007-01-23 | 2013-01-16 | Polaris SAS | Utilisation de dérivés polyphénoliques liposolubles comme antioxydants |
| ITMI20070555A1 (it) * | 2007-03-21 | 2007-06-20 | Giuliani Spa | Composizione provvista di attivita' di inibizione sulla 5 alfa-reduttasi |
| CA2680825C (en) | 2007-03-22 | 2013-10-29 | Cytotech Labs, Llc | Topical formulations having enhanced bioavailability |
| US9707274B2 (en) | 2007-06-08 | 2017-07-18 | Healthpartners Research & Education | Methods for preventing and treating post-traumatic stress disorder (PTSD) |
| JP5447954B2 (ja) | 2007-09-19 | 2014-03-19 | 公益財団法人名古屋産業科学研究所 | 神経栄養因子様作用剤 |
| US8143014B2 (en) * | 2007-10-02 | 2012-03-27 | Mayo Foundation For Medical Education And Research | CD38 and obesity |
| DE102008012988A1 (de) | 2008-03-07 | 2009-09-10 | S.W. Patentverwertungs Ltd. | Zusammensetzung und Verwendungen zur Beeinflussung des Haarwachstums |
| US8815953B2 (en) * | 2008-03-13 | 2014-08-26 | Spectrum Pharmaceuticals, Inc. | Formulations of vitamin K analogs for topical use |
| KR20100136997A (ko) | 2008-04-11 | 2010-12-29 | 싸이토테크 랩스, 엘엘씨 | 암세포에서 아폽토시스를 유도하는 방법 및 용도 |
| WO2010028187A2 (en) * | 2008-09-03 | 2010-03-11 | Bionovo, Inc. | Methods and compositions for the treatment of cancer |
| EP2378872A4 (en) | 2008-12-18 | 2012-05-16 | B Eugene Guthery | TREATMENT PLAN FOR ACNE VULGARIS |
| EP2424555A4 (en) * | 2009-04-28 | 2013-02-20 | Bionovo Inc | METHOD FOR REDUCING FAT COLLECTION AND CAUSING WEIGHT LOSS |
| CN102483419B (zh) | 2009-05-11 | 2017-12-15 | 博格有限责任公司 | 利用表观代谢转变剂、多维细胞内分子或环境影响剂诊断代谢障碍的方法 |
| CN102427807B (zh) * | 2009-05-21 | 2013-12-04 | 三得利控股株式会社 | 含有含苯并环庚三烯酚酮环化合物的抗肥胖剂 |
| US8163796B1 (en) * | 2009-07-28 | 2012-04-24 | BioChemical Solutions, LLC | Treatment of cancer by oxidation-reduction potentiation of cancerostatic dicarbonyls |
| CN102526004A (zh) * | 2010-01-25 | 2012-07-04 | 四川省中医药科学院 | 四氢姜黄素的新用途 |
| ES2664793T3 (es) * | 2010-03-12 | 2018-04-23 | Berg Llc | Formulaciones intravenosas de coenzima Q10 (CoQ10) y métodos de uso de las mismas |
| KR101247239B1 (ko) * | 2010-11-25 | 2013-03-26 | 아쿠아그린텍(주) | 디에콜을 함유하는 감태 추출물 또는 감태 유래 디에콜을 포함하는 탈모방지 또는 발모촉진용 조성물 |
| CN103608323B (zh) | 2011-04-04 | 2016-08-17 | 博格有限责任公司 | 治疗中枢神经系统肿瘤的方法 |
| AU2012271274B2 (en) | 2011-06-17 | 2017-07-27 | Berg Llc | Inhalable pharmaceutical compositions |
| US9884815B2 (en) * | 2011-10-14 | 2018-02-06 | Emory University | PGAM1 inhibitors and methods related thereto |
| KR101361147B1 (ko) * | 2012-06-27 | 2014-02-13 | 한국식품연구원 | 국화과 식물 추출물을 포함하는 ｈＴＲＰＡ１ 활성화 조성물 및 그의 용도 |
| US9301989B2 (en) | 2011-11-18 | 2016-04-05 | Korea Food Research Institute | hTRPA1-activating composition and use thereof |
| WO2013107413A1 (zh) * | 2012-01-19 | 2013-07-25 | 中国科学院上海巴斯德研究所 | 磷酸化途径相关因子在调控调节性t细胞功能中的应用 |
| JP5668001B2 (ja) * | 2012-03-05 | 2015-02-12 | 丸善製薬株式会社 | 皮膚化粧料及び頭髪化粧料 |
| US10279012B2 (en) | 2013-03-11 | 2019-05-07 | Healthpartners Research & Education | Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin |
| MX380565B (es) | 2013-04-08 | 2025-03-12 | Berg Llc | Terapias combinadas de coenzima q10 para el tratamiento de cáncer. |
| HUE050060T2 (hu) | 2013-09-04 | 2020-11-30 | Berg Llc | Eljárások rák kezelésére koenzim Q10 folyamatos infúziójával |
| US10172915B2 (en) * | 2013-10-20 | 2019-01-08 | Duke University | Methods and compositions for activation of sirtuins with Annexin A1 peptides |
| US10314911B2 (en) | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
| JP2016172705A (ja) * | 2015-03-17 | 2016-09-29 | 国立大学法人 東京大学 | Ｍｉｎｔ３阻害剤 |
| WO2017087576A1 (en) | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| WO2017103637A1 (en) | 2015-12-18 | 2017-06-22 | Blirt S.A. | Diphenylpropane compounds and their cytotoxic activity |
| JP7029777B2 (ja) * | 2016-03-28 | 2022-03-04 | 国立大学法人金沢大学 | アンドロゲン依存性又は非依存性前立腺癌細胞の抑制用の組成物及びそれを含有する前立腺癌の医薬製剤 |
| CN105949162B (zh) * | 2016-05-09 | 2018-02-09 | 许爱娥 | 咖啡酸衍生物在治疗白癜风中的应用 |
| WO2018085705A1 (en) | 2016-11-03 | 2018-05-11 | Repairogen Corp | Cosmetic compositions containing quinones and their topical use on skin and hair |
| US11013673B2 (en) | 2016-11-03 | 2021-05-25 | Repairogen Corp. | Cosmetic compositions containing quinones and their topical use on skin and hair |
| WO2019213494A1 (en) | 2018-05-03 | 2019-11-07 | Repairogen Corp | Cosmetic compositions containing quinones and their topical use on skin and hair |
| JP2020070242A (ja) * | 2018-10-29 | 2020-05-07 | アドファーマ株式会社 | 発毛および育毛改善剤 |
| KR102519649B1 (ko) * | 2019-10-31 | 2023-04-10 | 이주운 | 캠퍼롤 및 에피카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US176898A (en) * | 1876-05-02 | Improvement in compositions for preventing acid fermentation | ||
| US122777A (en) * | 1872-01-16 | Improvement in organ actions | ||
| DE2807407A1 (de) | 1978-02-17 | 1979-08-30 | Schering Ag | Testosteronester |
| JPS57118580A (en) | 1981-01-16 | 1982-07-23 | Kanebo Ltd | Novel catechin derivative |
| EP0116439A3 (en) | 1983-02-02 | 1986-01-29 | Suntory Limited | Fatty acid containing hair tonic composition |
| DE3514724A1 (de) * | 1985-04-24 | 1986-10-30 | Albin F. Dr. 4200 Oberhausen Jereb | Salbe zur verbeugung und behandlung von augen- und hauterkrankungen |
| JPS6284021A (ja) * | 1985-10-08 | 1987-04-17 | Shiseido Co Ltd | テストステロン−５α−レダクタ−ゼ阻害剤 |
| JPS6425726A (en) | 1987-04-24 | 1989-01-27 | Yuutoku Yakuhin Kogyo Kk | Agent for eliminating active oxygen free radical |
| EP0309086A1 (en) | 1987-09-07 | 1989-03-29 | Efamol Holdings Plc | Treatment of male pattern baldness and of unwanted hair growth |
| JPH0196124A (ja) * | 1987-10-07 | 1989-04-14 | Fujirebio Inc | 制癌剤 |
| JP2753607B2 (ja) * | 1988-08-11 | 1998-05-20 | 一丸ファルコス株式会社 | テストステロン５α−リダクターゼ阻害剤 |
| JPH02300120A (ja) | 1989-05-11 | 1990-12-12 | Nippon Oil & Fats Co Ltd | 制癌剤 |
| JPH03141220A (ja) * | 1989-10-26 | 1991-06-17 | Tsumura & Co | 抗レトロウイルス剤 |
| JPH07112979B2 (ja) | 1991-11-13 | 1995-12-06 | 株式会社スカイ・フード | 活性酸素フリーラジカル消去剤 |
| JP3211191B2 (ja) | 1992-03-31 | 2001-09-25 | 太陽化学株式会社 | 茶抽出物組成物 |
| US5422371A (en) | 1992-05-27 | 1995-06-06 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
| US5605929A (en) | 1992-05-27 | 1997-02-25 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
| JPH06128168A (ja) | 1992-10-14 | 1994-05-10 | Suetsuna Yoko | 抗変異原活性並びにスーパーオキシドジムスターゼ様活性を有 する茶カテキン類 |
| JPH07112980B2 (ja) | 1992-11-04 | 1995-12-06 | 株式会社スカイ・フード | 活性酸素フリーラジカル消去剤 |
| FR2699818B1 (fr) | 1992-12-24 | 1995-02-03 | Oreal | Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko. |
| US5306486A (en) | 1993-03-01 | 1994-04-26 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic sunscreen composition containing green tea and a sunscreen |
| CN1079361A (zh) | 1993-04-24 | 1993-12-15 | 河南中医学院 | 速溶绿茶及其加工工艺 |
| FR2711060B1 (fr) * | 1993-10-13 | 1995-11-17 | Oreal | Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet. |
| WO2004073726A1 (ja) * | 1993-10-21 | 2004-09-02 | Keiichi Togasaki | 活性酸素フリーラジカル消去剤 |
| IL112205A0 (en) * | 1994-01-06 | 1995-03-15 | Res Dev Foundation | Curcumin, analogues of curcumin and novel uses thereof |
| DE4444238A1 (de) | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
| FR2734478B1 (fr) | 1995-05-23 | 1997-07-11 | Berkem Sa | Composition cosmetique ou pharmaceutique utilisable par voie topique ou orale ayant des proprietes antiradicalaires et un pouvoir filtrant vis-a-vis des uv |
| JPH08337510A (ja) * | 1995-06-15 | 1996-12-24 | Advanced Sukin Res Kenkyusho:Kk | メラニン生成抑制剤 |
| JPH09176011A (ja) * | 1995-12-27 | 1997-07-08 | Kureha Chem Ind Co Ltd | Ｈｓｐ２７ファミリーに属するタンパク質のフラボノイド含有合成抑制剤 |
| JP2000504020A (ja) * | 1996-01-31 | 2000-04-04 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ＨＥＲ２／ｎｅｕを過剰発現するガン細胞の化学療法剤に対する感作 |
| US6261565B1 (en) * | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
| JPH09315985A (ja) | 1996-05-29 | 1997-12-09 | Kanebo Ltd | 突然変異抑制剤 |
| DE19627344A1 (de) | 1996-07-01 | 1998-01-08 | Vitasyn Gmbh Entwicklung & Ver | Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenolverbindungen |
| US5665393A (en) | 1996-09-03 | 1997-09-09 | International Medical Research, Inc. | Herbal composition for treating prostate carcinoma |
| US5665367A (en) | 1996-09-27 | 1997-09-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing naringenin and/or quercetin and a retinoid |
| US6337320B1 (en) | 1996-10-11 | 2002-01-08 | Thione International, Inc. | Reparatives for ultraviolet radiation skin damage |
| US6197808B1 (en) | 1996-11-18 | 2001-03-06 | Cancer Instititute (Hospital), Chinese Academy Of Medical Sciences | Methods for treating hyperplasia |
| US5804594A (en) | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
| US5804168A (en) | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
| US5962517A (en) | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
| WO1998048790A1 (en) * | 1997-04-28 | 1998-11-05 | Anticancer, Inc. | Use of genistein and related compounds to treat certain sex hormone related conditions |
| JP4738592B2 (ja) | 1997-10-31 | 2011-08-03 | アーチ・デヴェロップメント・コーポレイション | ５α−還元酵素活性を調節するための方法及び組成物 |
| US6696484B2 (en) * | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| KR20010041938A (ko) | 1998-03-16 | 2001-05-25 | 데이비드 엠 모이어 | 피부 외형을 조절하는 방법 |
| FR2778663B1 (fr) * | 1998-05-15 | 2001-05-18 | Coletica | Nouveaux esters de flavonoides,leur utilisation en cosmetique, dermopharmacie, en pharmacie et en agro-alimentaire |
| FR2780647B1 (fr) | 1998-07-03 | 2002-03-08 | Lanatech | Composition cosmetique exploitant des effets antiradicalaires synergiques |
| EP1094781B1 (en) * | 1998-07-07 | 2008-07-02 | Transdermal Technologies Inc. | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
| GB9814733D0 (en) | 1998-07-07 | 1998-09-02 | Unilever Plc | Method of reducing or preventing malodour |
| DE29813269U1 (de) | 1998-07-25 | 1998-11-05 | Schmitt Angelo | Tablette |
| US6410052B1 (en) | 1999-03-30 | 2002-06-25 | Purdue Research Foundation | Tea catechins in sustained release formulations as cancer specific proliferation inhibitors |
| US6428818B1 (en) | 1999-03-30 | 2002-08-06 | Purdue Research Foundation | Tea catechin formulations and processes for making same |
| US6156912A (en) | 1999-04-09 | 2000-12-05 | Mars, Incorporated | 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation |
| AU7561300A (en) * | 1999-09-23 | 2001-04-24 | Universiteit Van Maastricht | Novel flavonoids |
| WO2001026668A1 (en) | 1999-10-14 | 2001-04-19 | Unilever N.V. | Compositions with anti-prostate cancer activity |
| FI20000004A0 (fi) | 2000-01-03 | 2000-01-03 | Slk Foundation | Flavonoidilääke... |
| US6248341B1 (en) | 2000-01-14 | 2001-06-19 | Color Access, Inc. | Method of treating topical angiogenesis-related disorders |
| ATE276736T1 (de) | 2000-04-04 | 2004-10-15 | Color Access Inc | Zubereitung zur verbesserung der epithelialen lipidbarrierefunktion |
-
1998
- 1998-10-30 JP JP2000518662A patent/JP4738592B2/ja not_active Expired - Lifetime
- 1998-10-30 KR KR1020007004542A patent/KR20010031501A/ko not_active Withdrawn
- 1998-10-30 EP EP98956358A patent/EP1027045A4/en not_active Withdrawn
- 1998-10-30 WO PCT/US1998/023041 patent/WO1999022728A1/en not_active Application Discontinuation
- 1998-10-30 AU AU12898/99A patent/AU1289899A/en not_active Abandoned
- 1998-10-30 US US09/530,443 patent/US6576660B1/en not_active Expired - Lifetime
-
2002
- 2002-11-14 US US10/294,331 patent/US20030144346A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003524577A5 (ja) | ||
| KR910004651A (ko) | 5α-환원효소 억제제로서의 17β-아실-4-아자-5α-안드로스트-1-엔-3-온 | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| EP1212055A4 (en) | NEUROTHERAPEUTIC COMPOSITION AND METHOD | |
| CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
| BR0110420A (pt) | Agonistas muscarìnicos | |
| MXPA05006940A (es) | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. | |
| ATE422357T1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| DE69733834D1 (de) | Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren | |
| DE60045751D1 (de) | Therapeutische Behandlung androgenrezeptorbedingter Leiden | |
| DE69912432D1 (de) | Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide | |
| DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
| SE0104248D0 (sv) | Method of treatment | |
| JP2714402B2 (ja) | 癌転移抑制剤 | |
| BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
| ATE249233T1 (de) | Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen | |
| EP1458734A4 (en) | ISOINDIGO, INDIGO AND INDIRUBIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | |
| KR950031085A (ko) | 표피증식 질환 치료용 의약 조성물 | |
| DE60011794D1 (de) | Verwendung von docetaxel für die behandlung von hepatozelluläre krebs | |
| RU94045271A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера | |
| DE60030107D1 (de) | Vitamin-d derivate zur behandlung des systemischen lupus erythematodes | |
| ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| DE69822626D1 (de) | Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs | |
| ATE293972T1 (de) | Behandlung von chronischen schmerzen | |
| RU2007143434A (ru) | 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний |